Hereditary Angioedema: A Review of the Current and Evolving Treatment Landscape

J Allergy Clin Immunol Pract. 2023 Aug;11(8):2315-2325. doi: 10.1016/j.jaip.2023.04.017. Epub 2023 Apr 26.

Abstract

Hereditary angioedema (HAE) is a rare disease characterized by sudden and often unprovoked episodes of swelling that can be potentially life-threatening when it involves the upper airway. The treatment options for both acute episodes of HAE and LTP, used to minimize the frequency and severity of angioedema attacks, were limited historically to very few options, had considerable side effects, and/or had considerable burden of treatment. Fortunately, through the elucidation of the pathophysiology of HAE, the development of newer targeted therapies has been possible both for acute therapy and long-term prophylaxis and even more are on the horizon. Because of the rapid development of these therapies, it can be challenging for clinicians to keep abreast of newer and developing treatments for HAE. This review article will outline the current and potential future treatments for HAE. It will also highlight important considerations when treating special HAE patient populations including women and pediatric patients.

Keywords: Hereditary angioedema.

Publication types

  • Review

MeSH terms

  • Angioedema* / drug therapy
  • Angioedemas, Hereditary* / diagnosis
  • Angioedemas, Hereditary* / drug therapy
  • Child
  • Complement C1 Inhibitor Protein / therapeutic use
  • Female
  • Humans

Substances

  • Complement C1 Inhibitor Protein